January 21, 2021 -- Kuur Therapeutics has released results from phase I clinical trials evaluating its off-the-shelf chimeric antigen receptor natural killer T (CAR-NKT)-cell immunotherapy candidates in relapsed/refractory (R/R) neuroblastoma and R/R CD19-positive malignancies.
In the GinaKit2 study of KUR-501 (autologous GD2 CAR-NKT cells) in patients with R/R neuroblastoma, the company observed one complete result in ten patients, and tumor biopsies showed CAR-NKT cells homing to the neuroblastoma tumor site at all dose levels. The candidate has so far demonstrated a promising safety profile. In the Anchor study of KUR-502 (off-the-shelf CD19 CAR-NKT cells) in patients with R/R CD19-positive malignancies, two patients have been treated with either complete or partial responses.
The trials are being conducted at Baylor College of Medicine (Kuur's CAR-NKT cell platform partner), Houston Methodist Hospital, and Texas Children's Hospital.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
